FINANCIAL INFORMATION CONCERNING THE GROUP’S ASSETS AND LIABILITIES, FINANCIAL POSITIONAND PROFITS AND LOSSES 20 Details and main characteristics of the SO granted to date SO 2017 SO 2017 Date of grant July 27, 2017 December 19, 2017 Plan expiration date July 26, 2024 December 18, 2024 Number of warrants initially granted 220,000 300,000 Exercise price €5.04 €5.55 Share entitlement per warrant 1 1 Valuation method Black & Scholes Expected volatility 51.09% 50.36% Expected dividend 0.00% 0.00% Fair value per option €2.09 €2.20 Changes in the balances of SO SO 2017 Balance outstanding at January 1, 2017 — Granted during the period 520,000 Exercised during the period — Forfeited during the period (155,834) Balance outstanding at December 31, 2017 364,166 Of which exercisable 139,166 16.5 Reconciliation with P&L share-based expense As of December 31, 2016 As of December 31, 2017 In thousands of euros R&D G&A TOTAL R&D G&A S&M TOTAL Non-Employee Warrants (BSA) 202 234 437 381 189 — 570 Employee Warrants (BCE) 721 1,093 1,815 (91) 286 — 195 Performance Shares (AGA) 923 1,461 2,383 931 2,769 13 3,714 Stock Options (SO) — — — 322 — — 322 Share-based payments expense 1,847 2,788 4,635 1,543 3,245 13 4,800 206– GENSIGHT BIOLOGICS – 2017 Registration Document